Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50745
Name diffuse large B-cell lymphoma
Definition A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma diffuse large B-cell lymphoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PTEN loss Idelalisib + MK2206 diffuse large B-cell lymphoma predicted - sensitive detail...
PTEN loss GSK2334470 + Idelalisib diffuse large B-cell lymphoma predicted - sensitive detail...
BRAF V600E ERAS-007 diffuse large B-cell lymphoma sensitive detail...
ALK I1171N ALK pos Lorlatinib diffuse large B-cell lymphoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00001337 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Active, not recruiting USA 0
NCT00006436 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Prednisone + Rituximab + Vincristine Sulfate EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection Active, not recruiting USA 0
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated USA 0
NCT00918463 Phase II Dasatinib A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated USA 0
NCT00978432 Phase II Everolimus + Panobinostat Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA | GBR | FRA | ESP 0
NCT01193842 Phase Ib/II Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Completed USA 0
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA 1
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed USA | ITA | FRA | AUS 1
NCT01334502 Phase I Everolimus Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma Completed USA 0
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Completed USA | ITA | FRA | ESP | BEL 0
NCT01431209 Phase II Ruxolitinib Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma Completed USA 0
NCT01449461 Phase Ib/II Brigatinib A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Completed 0
NCT01453205 Phase II Cisplatin + Cytarabine + Dexamethasone Carboplatin + Etoposide + Ifosfamide Rituximab MEDI-551 A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | FRA | ESP | DEU | CAN 6
NCT01686165 Phase II Belinostat Rituximab Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Completed USA 0
NCT01691898 Phase Ib/II Obinutuzumab + Pinatuzumab Vedotin + Rituximab Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab Obinutuzumab + Polatuzumab vedotin-piiq A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS) Completed USA | NLD | ITA | FRA | DEU | CAN 0
NCT01719250 Phase I Buparlisib Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed USA 0
NCT01742988 Phase Ib/II Bendamustine + CUDC-907 + Rituximab CUDC-907 + Rituximab CUDC-907 CUDC-907 + Venetoclax Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma Completed USA 0
NCT01799889 Phase II Entospletinib A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies Terminated USA | CAN 0
NCT01804686 Phase III Ibrutinib A Long-term Extension Study of PCI-32765 (Ibrutinib) Enrolling by invitation USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 20
NCT01811368 Phase II anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT01854606 Phase Ib/II Everolimus + Sotrastaurin Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma Completed USA | NLD | ITA | FRA | DEU 3
NCT01855750 Phase III Ibrutinib Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed USA | NLD | GBR | FRA | ESP | DEU | CAN | BEL | AUS 18
NCT01859819 Phase II Cytarabine + Rituximab Treatment for Advanced B-Cell Lymphoma Completed USA 0
NCT01897012 Phase I Romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed USA 0
NCT01938638 Phase I BAY1143572 Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Completed USA 3
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Completed 0
NCT01955499 Phase I Ibrutinib + Lenalidomide Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting USA | CAN 0
NCT01959698 Phase Ib/II Carfilzomib + Rituximab Carboplatin + Etoposide + Ifosfamide Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Active, not recruiting USA 0
NCT01992653 Phase I Cyclophosphamide + Doxorubicin + Prednisone Rituximab Polatuzumab vedotin-piiq Obinutuzumab A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma Completed USA | FRA 0
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Completed USA 0
NCT02000934 Phase I Mivavotinib A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Completed USA | ITA | GBR | ESP 0
NCT02029443 Phase Ib/II Acalabrutinib ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia Active, not recruiting USA | ITA | GBR 0
NCT02031419 Phase I CC-122 + Spebrutinib Onatasertib + Spebrutinib CC-122 + Onatasertib Rituximab Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma Terminated USA | ITA | FRA | CAN 0
NCT02055820 Phase I Venetoclax Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Obinutuzumab A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma Completed USA | NLD | ITA | FRA | ESP | CAN | AUT | AUS 2
NCT02061761 Phase Ib/II Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Completed USA | CAN 0
NCT02073097 Phase Ib/II Carfilzomib + Rituximab Cyclophosphamide + Doxorubicin + Vincristine Sulfate Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma Unknown status USA 0
NCT02077166 Phase Ib/II Ibrutinib + Lenalidomide + Rituximab Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Completed USA | GBR | DEU | BEL 0
NCT02082977 Phase I GSK126 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma Terminated USA | GBR | FRA 0
NCT02106091 Phase I AFM11 Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Terminated USA | DEU 2
NCT02138786 Phase II Selinexor Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT) Terminated USA | GBR | ESP | DEU 1
NCT02141451 Phase Ib/II INCB7839 + Rituximab ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL Completed USA 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02181218 Phase I Pegfilgrastim Romidepsin Dexamethasone + Gemcitabine + Oxaliplatin Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Completed USA 0
NCT02203526 Phase I Dexamethasone + Etoposide + Ibrutinib + Pegylated liposomal doxorubicin + Temozolomide Cytarabine Rituximab Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma Recruiting USA 0
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed USA 0
NCT02219737 Phase I Ibrutinib Carboplatin + Etoposide + Ifosfamide + Rituximab Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Completed USA 0
NCT02220842 Phase I Atezolizumab + Obinutuzumab A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma Completed USA | ITA | GBR | FRA | DEU 0
NCT02226965 Phase II PNT2258 Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL Completed USA 1
NCT02227251 Phase II Selinexor Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL) Recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 7
NCT02229981 Phase Ib/II ABC294640 An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma Withdrawn USA 0
NCT02252146 Phase Ib/II Bazlitoran Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation Completed USA 0
NCT02257567 Phase Ib/II Bendamustine + Rituximab Polatuzumab vedotin-piiq Obinutuzumab A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 4
NCT02282358 Phase Ib/II Mocetinostat Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Terminated USA 0
NCT02303392 Phase I Ibrutinib + Selinexor Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Unknown status USA 0
NCT02315326 Phase Ib/II Ibrutinib Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) Recruiting USA 0
NCT02323230 Phase II Cyclophosphamide + Maveropepimut-S A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL Terminated CAN 0
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA | GBR 0
NCT02343536 Phase I Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Azacitidine A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma Completed USA 0
NCT02348216 Phase Ib/II axicabtagene ciloleucel A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) Completed USA | NLD | FRA | DEU | CAN 1
NCT02361346 Phase Ib/II MT-3724 Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001) Terminated USA | ESP | CAN 7
NCT02362997 Phase II Pembrolizumab Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL Completed USA 0
NCT02376699 Phase I Pembrolizumab + SEA-CD40 SEA-CD40 Safety Study of SEA-CD40 in Cancer Patients Terminated USA 0
NCT02391116 Phase II Copanlisib Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Completed ITA | GBR | FRA | DEU | CAN | BEL | AUS 3
NCT02393157 Phase II Carboplatin + Etoposide + Ifosfamide + Obinutuzumab Cytarabine Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE) Recruiting USA 0
NCT02399085 Phase II Lenalidomide + Tafasitamab-cxix A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL Completed USA | ITA | GBR | FRA | ESP | DEU | BEL 3
NCT02401048 Phase Ib/II Durvalumab + Ibrutinib A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Completed USA 0
NCT02408042 Phase Ib/II Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) Withdrawn USA 0
NCT02420795 Phase Ib/II ONC201 Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Terminated USA 0
NCT02436707 Phase II Ibrutinib Cisplatin + Dexamethasone + Gemcitabine + Rituximab Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma Recruiting CAN 0
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated USA 1
NCT02443077 Phase III Cyclophosphamide Carmustine + Cytarabine + Etoposide + Melphalan Ibrutinib Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Active, not recruiting USA 1
NCT02445248 Phase II Tisagenlecleucel Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET) Completed USA | NLD | ITA | FRA | DEU | CAN | AUT | AUS 2
NCT02454270 Phase II JNJ-64052781 A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies Terminated USA | FRA | ESP | BEL 1
NCT02457598 Phase I Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Active, not recruiting USA | GBR | FRA 0
NCT02471911 Phase I Dexamethasone Carboplatin + Etoposide + Ifosfamide + Rituximab Selinexor KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma Completed USA 0
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Completed USA | FRA | ESP | DEU | BEL 1
NCT02530125 Phase II Pidilizumab Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission Terminated USA 0
NCT02531308 Phase II Metformin Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Pegfilgrastim Rituximab Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) Terminated USA 0
NCT02532192 Phase I Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma Withdrawn 0
NCT02541565 Phase I Pembrolizumab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Rituximab Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma Completed USA 0
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Completed USA 0
NCT02549651 Phase I Durvalumab + Tremelimumab Durvalumab Danvatirsen + Durvalumab MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023) Completed USA | GBR | FRA 1
NCT02564744 Phase II Naratuximab Emtansine + Rituximab Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL Completed USA | ITA | BEL 6
NCT02570542 Phase II Plerixafor Carmustine + Cytarabine + Etoposide + Melphalan Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) Active, not recruiting USA 0
NCT02572453 Phase II Onalespib Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) Terminated USA 0
NCT02576990 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170) Completed 0
NCT02580552 Phase I MRG-106 Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Completed USA 0
NCT02581631 Phase Ib/II Brentuximab vedotin + Nivolumab A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) Completed USA | ITA | GBR | FRA | ESP | CAN 0
NCT02589145 Phase Ib/II Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Terminated USA 0
NCT02596971 Phase Ib/II Atezolizumab + Bendamustine + Obinutuzumab Atezolizumab + Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Atezolizumab + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | ITA | AUS 0
NCT02600897 Phase Ib/II Lenalidomide + Rituximab Lenalidomide + Obinutuzumab Lenalidomide + Polatuzumab vedotin-piiq + Rituximab Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | GBR | ESP 0
NCT02611323 Phase Ib/II Polatuzumab vedotin-piiq + Rituximab + Venetoclax Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | ITA | AUS 0
NCT02624986 Phase Ib/II Idasanutlin + Obinutuzumab A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Terminated USA | NZL | DEU | AUS 1
NCT02628405 Phase Ib/II Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Rituximab R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting USA 0
NCT02631044 Phase I Lisocabtagene maraleucel Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Active, not recruiting USA 0
NCT02636322 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate Ibrutinib + Lenalidomide + Rituximab Prednisone A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma Completed USA 0
NCT02650999 Phase Ib/II Pembrolizumab Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas Completed USA 0
NCT02658968 Phase I Betalutin Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) Completed USA | ITA | GBR | ESP | DEU 0
NCT02674750 Phase II CUDC-907 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations Completed USA | ESP 0
NCT02681302 Phase Ib/II Ipilimumab + Nivolumab Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001) Active, not recruiting USA 0
NCT02684617 Phase I Dinaciclib + Pembrolizumab Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) Terminated 0
NCT02698189 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005) Terminated 0
NCT02700022 Phase I Alisertib Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas Terminated USA 0
NCT02701673 Phase Ib/II Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Withdrawn 0
NCT02706405 Phase I Cyclophosphamide + Durvalumab + JCAR014 JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Terminated USA 0
NCT02729896 Phase Ib/II Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | DEU 1
NCT02734771 Phase II Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting USA 0
NCT02743546 Phase I Ibrutinib + JNJ-64052781 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma Withdrawn 0
NCT02756247 Phase I Buparlisib + Ibrutinib A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma Completed USA 0
NCT02760485 Phase Ib/II Ibrutinib + Itacitinib A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Completed USA 0
NCT02763254 Phase II CMD-003 Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC) Terminated USA 0
NCT02763319 Phase II Bendamustine + Tafasitamab-cxix Bendamustine + Rituximab A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 13
NCT02776813 Phase I ACTR087 + Rituximab Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Completed USA 0
NCT02793583 Phase II Umbralisib Ublituximab + Umbralisib Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL) Terminated USA | ITA | GBR | ESP | AUS 4
NCT02815397 Phase II Metformin DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma Terminated USA 0
NCT02874404 Phase II Ibrutinib + Umbralisib TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Completed USA 0
NCT02875002 Phase I Belinostat + Volasertib Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Withdrawn USA 0
NCT02875223 Phase I CC-90011 A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas Terminated ITA | GBR | FRA | ESP 1
NCT02889523 Phase Ib/II Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Tazemetostat + Vincristine Sulfate Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP) Active, not recruiting FRA | BEL 0
NCT02900651 Phase Ib/II MAK683 Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 4
NCT02909777 Phase I CUDC-907 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Active, not recruiting USA 0
NCT02914938 Phase I zandelisib Rituximab + zandelisib A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Terminated USA 1
NCT02926833 Phase Ib/II Atezolizumab + axicabtagene ciloleucel A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) Completed USA 0
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Terminated USA 0
NCT02950220 Phase I Ibrutinib + Pembrolizumab Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed USA 0
NCT02951156 Phase III Avelumab + Azacitidine + Utomilumab Avelumab + Rituximab + Utomilumab Bendamustine + Rituximab Gemcitabine + Oxaliplatin + Rituximab Avelumab + Bendamustine + Rituximab Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) Terminated USA | ITA | GBR | ESP | BEL | AUS 2
NCT02953509 Phase Ib/II Hu5F9-G4 + Rituximab Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Active, not recruiting USA | GBR | AUS 0
NCT02961816 Phase II Pyridoxine Busulfan + Gemcitabine + Melphalan + Panobinostat Dexamethasone + Filgrastim + Palifermin + Rituximab Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Withdrawn 0
NCT02998476 Phase II Parsaclisib A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) Completed USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 3
NCT03003520 Phase II Cyclophosphamide + Doxorubicin + Durvalumab + Lenalidomide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Durvalumab + Prednisone + Rituximab + Vincristine Sulfate A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma Completed USA | GBR | AUT 2
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Active, not recruiting USA 0
NCT03019640 Phase II Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma Completed USA 0
NCT03028103 Phase I Fluconazole + Tazemetostat Omeprazole + Repaglinide + Tazemetostat Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects Completed USA 0
NCT03036904 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R) Completed USA 0
NCT03049449 Phase I ATLCAR.CD30 cells Cyclophosphamide + Fludarabine T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Completed USA 0
NCT03064867 Phase I Carboplatin + Etoposide + Ifosfamide + Rituximab + Venetoclax Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting USA 0
NCT03085173 Phase I EGFRt/19-28z/4-1BBL CAR T cells A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Active, not recruiting USA 0
NCT03103971 Phase I Cyclophosphamide + Fludarabine + HuJCAR014 huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Terminated USA 0
NCT03106428 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies Completed USA | FRA 1
NCT03123393 Phase II Mivavotinib TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated USA | ITA | GBR | FRA | ESP | CAN 0
NCT03129828 Phase Ib/II Bortezomib + Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI >= 2 (ImbruVeRCHOP) Active, not recruiting DEU 0
NCT03135262 Phase Ib/II Idasanutlin + Rituximab + Venetoclax Idasanutlin + Obinutuzumab + Venetoclax Idasanutlin + Obinutuzumab + Rituximab + Venetoclax A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) Terminated USA | NZL | DEU | AUS 1
NCT03136497 Phase I Ibrutinib + Rituximab + Venetoclax A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Active, not recruiting USA 0
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT03150329 Phase I Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma Active, not recruiting USA 0
NCT03153462 Expanded access axicabtagene ciloleucel + Cyclophosphamide + Fludarabine Axicabtagene Ciloleucel Expanded Access Study Approved for marketing USA 0
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Active, not recruiting USA 0
NCT03188965 Phase I Elimusertib First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Completed USA | GBR | CAN 4
NCT03189836 Phase I ACTR707 + Rituximab Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Terminated USA 0
NCT03205046 Phase Ib/II Acalabrutinib + Vistusertib A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies Terminated USA | GBR 0
NCT03206671 Phase III Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Vincristine Sulfate Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (B-NHL 2013) Recruiting DEU | AUT 6
NCT03207867 Phase II Spartalizumab + Taminadenant A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Terminated USA | NLD | ITA | FRA | ESP | DEU | BEL | AUT | AUS 6
NCT03220022 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Ibrutinib + Pegfilgrastim + Prednisone + Rituximab + Vincristine Sulfate Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas Recruiting USA 0
NCT03220347 Phase I CC-90010 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas Active, not recruiting ITA | FRA | ESP 1
NCT03244176 Phase I Avelumab Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study (AvR-CHOP) Active, not recruiting AUS 0
NCT03255018 Phase II Pembrolizumab Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas Completed USA 0
NCT03255096 Phase I Rituximab + TEN-010 + Venetoclax A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed USA | ESP | AUS 1
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Active, not recruiting USA 0
NCT03263026 Phase III Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Enzastaurin Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1 Completed USA 1
NCT03274492 Phase III Polatuzumab vedotin-piiq Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 12
NCT03277729 Phase Ib/II CD20 CAR T-cells + Cyclophosphamide + Fludarabine A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Recruiting USA 0
NCT03283202 Phase I CC-122 + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors Completed USA | ESP | CAN | BEL 0
NCT03287817 Phase Ib/II Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) Completed USA | GBR 0
NCT03297424 Phase Ib/II PLX2853 A Study of PLX2853 in Advanced Malignancies. Completed USA 0
NCT03305445 Phase Ib/II Ipilimumab + Nivolumab Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL Completed USA 0
NCT03309878 Phase Ib/II Pembrolizumab Mogamulizumab + Pembrolizumab Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas Completed USA 0
NCT03311958 Phase I Nivolumab Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance Active, not recruiting USA 0
NCT03316573 Phase II Pembrolizumab A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas Suspended USA 0
NCT03321643 Phase I Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab Atezolizumab + Rituximab Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma Active, not recruiting USA 0
NCT03349450 Phase II Cyclophosphamide + Maveropepimut-S + Pembrolizumab Maveropepimut-S DPX-Survivac and Checkpoint Inhibitor in DLBCL (SPiReL) Completed CAN 0
NCT03352765 Phase I Bendamustine + Melphalan + Rituximab A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients Active, not recruiting USA 0
NCT03356054 Phase Ib/II Brentuximab vedotin + Cisplatin + Cytarabine + Dexamethasone + Rituximab Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (HOVON 136 NHL) Recruiting NLD 0
NCT03357627 Phase I Mivavotinib + Venetoclax A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma Completed USA | DEU | CAN 0
NCT03365791 Phase II Ieramilimab Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03379493 Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Terminated USA 0
NCT03391466 Phase III axicabtagene ciloleucel A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 3
NCT03399513 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Ibrutinib + Prednisolone + Rituximab + Vincristine Sulfate Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma (R-CHOEP-brut) Completed DEU 0
NCT03418038 Phase II Dexamethasone Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Rituximab Cytarabine + Dexamethasone + Oxaliplatin Gemcitabine + Oxaliplatin Cisplatin + Cytarabine + Dexamethasone + Rituximab Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma Recruiting USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Terminated USA | FRA | ESP | DEU 2
NCT03424122 Phase I Ibrutinib + Parsaclisib Bendamustine + Parsaclisib + Rituximab Parsaclisib + Rituximab INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Completed USA | ITA | ESP 0
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Active, not recruiting USA 0
NCT03440567 Phase I Avelumab + Carboplatin + Etoposide + Ifosfamide + Rituximab + Utomilumab Avelumab + Ibrutinib + Rituximab + Utomilumab Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Active, not recruiting USA 0
NCT03460977 Phase I PF-06821497 PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting USA | ESP 6
NCT03467373 Phase I Tocilizumab Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Glofitamab-gxbm Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisone + Rituximab + Vincristine Sulfate A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 1
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT03483103 Phase II Lisocabtagene maraleucel Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) Completed USA 0
NCT03484702 Phase II Lisocabtagene maraleucel Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD) Completed NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT 3
NCT03484819 Phase II Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma Active, not recruiting USA 0
NCT03488251 Phase II Gemcitabine + MT-3724 + Oxaliplatin PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Terminated USA 0
NCT03495960 Phase II Rituximab + Temozolomide Lenalidomide + Methotrexate + Procarbazine + Rituximab Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA) Recruiting ITA 4
NCT03537482 Phase I APG-2575 APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies Recruiting USA | AUS 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03543813 Phase Ib/II CX-2029 PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL Completed USA | GBR | ESP 1
NCT03547115 Phase I Voruciclib A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies Recruiting USA 0
NCT03558750 Phase Ib/II Lenalidomide + Nivolumab + Rituximab Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma Terminated USA 0
NCT03571828 Phase I AMG562 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma Terminated USA | DEU | CAN | BEL 0
NCT03586024 Phase Ib/II Pembrolizumab Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL) Withdrawn USA 0
NCT03589469 Phase II Loncastuximab tesirine-lpyl Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Completed USA | ITA | GBR 1
NCT03598608 Phase Ib/II MK-4280 + Pembrolizumab Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) Recruiting USA | ITA | DEU | CAN | AUS 1
NCT03610061 Phase I Durvalumab A Trial of Radiotherapy and Durvalumab in DLBCL and FL (RaDD) Completed AUS 0
NCT03610724 Phase II Tisagenlecleucel Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 4
NCT03625037 Phase Ib/II Epcoritamab-bysp First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 6
NCT03630159 Phase I Pembrolizumab + Tisagenlecleucel Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (PORTIA) Completed USA | CAN | AUT 0
NCT03645395 Phase II Lenalidomide + MT-3724 PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) Terminated USA 0
NCT03671018 Phase I Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Polatuzumab vedotin-piiq + Rituximab Bendamustine + Obinutuzumab Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb Obinutuzumab Tocilizumab A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Active, not recruiting USA | GBR | ESP | CAN | BEL 0
NCT03677141 Phase Ib/II Tocilizumab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone + Vincristine Sulfate A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Completed USA | FRA | ESP | AUT 2
NCT03677154 Phase Ib/II Mosunetuzumab-axgb + Tocilizumab A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy Active, not recruiting USA | ESP 4
NCT03682796 Phase I TRPH-222 Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Completed USA | CAN 0
NCT03685344 Phase I Durvalumab + Loncastuximab tesirine-lpyl Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma Terminated USA | ESP 0
NCT03688451 Phase II Rituximab Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma Active, not recruiting USA 0
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Recruiting USA 0
NCT03703167 Phase I Ibrutinib + Lenalidomide + Rituximab Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) Active, not recruiting USA 0
NCT03704714 Phase Ib/II Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Suspended USA 0
NCT03731234 Phase II Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance Recruiting ITA 0
NCT03740529 Phase Ib/II Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Active, not recruiting USA | ITA | GBR | FRA | AUS 5
NCT03742258 Phase I Cyclophosphamide + Doxorubicin + Mivavotinib + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma Unknown status USA 0
NCT03743246 Phase Ib/II Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) Completed USA | NLD | ITA | FRA | ESP | DEU 0
NCT03744676 Phase II Lisocabtagene maraleucel A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Completed USA 0
NCT03755154 Phase I VOB560 Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia Completed GBR | FRA | ESP | AUS 0
NCT03758989 Phase II Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma Recruiting USA 0
NCT03797261 Phase I AMG 176 + Venetoclax A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies Terminated USA | DEU | AUS 0
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Completed USA 0
NCT03843294 Phase I MultiTAA-specific T cells + Nivolumab Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma Active, not recruiting USA 0
NCT03876028 Phase I Ibrutinib + Tisagenlecleucel Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients Terminated USA 0
NCT03884998 Phase I Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma Active, not recruiting USA 0
NCT03886831 Phase I PRT543 A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Completed USA 0
NCT03892044 Phase I Duvelisib + Nivolumab Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Completed USA 0
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Active, not recruiting USA | ESP | CAN | BEL 0
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Withdrawn USA 0
NCT03934814 Phase I Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Completed USA 1
NCT03939026 Phase I UCART19 ALLO-647 + Cyclophosphamide + Fludarabine Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA) Active, not recruiting USA 0
NCT03939182 Phase Ib/II Abexinostat + Ibrutinib Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma Active, not recruiting USA 0
NCT03943901 Phase II Cyclophosphamide + Doxorubicin + Pegfilgrastim + Prednisone + Rituximab + Vincristine Sulfate Split-Dose R-CHOP for Older Adults With DLBCL Recruiting USA 0
NCT03955783 Phase I Selinexor + Venetoclax Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies Active, not recruiting USA 0
NCT03960840 Phase I Ibrutinib + YTB323 YTB323 CD19-specific CAR-T Cells in CLL/SLL and DLBCL Recruiting USA | ITA | FRA | ESP | DEU | AUT | AUS 1
NCT03984448 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Active, not recruiting USA 0
NCT03990961 Phase II Pembrolizumab Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) Recruiting USA 0
NCT03995147 Phase II Cyclophosphamide + Doxorubicin + Pembrolizumab + Prednisone + Rituximab + Vincristine Sulfate Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma Recruiting USA 0
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Active, not recruiting USA 0
NCT04002401 Phase II axicabtagene ciloleucel + Cyclophosphamide + Fludarabine + Rituximab Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma Completed USA 0
NCT04002947 Phase II Acalabrutinib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT04007029 Phase I Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Recruiting USA 0
NCT04072458 Phase I BP1002 A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Recruiting USA 0
NCT04074330 Phase Ib/II Rituximab + Subasumstat A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN 2
NCT04082936 Phase I IGM-2323 A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Active, not recruiting USA | ITA | FRA | ESP | AUS 2
NCT04088864 Phase I Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Active, not recruiting USA 0
NCT04088890 Phase I Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Active, not recruiting USA 0
NCT04094311 Phase III Tisagenlecleucel Study of Out of Specification for Tisagenlecleucel Recruiting CAN 1
NCT04113226 Phase II Rituximab Lenalidomide + Rituximab Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma (Relyage) Recruiting FRA 0
NCT04134936 Phase I Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL Completed USA | ITA | FRA | ESP | DEU | BEL | AUT 2
NCT04136275 Phase I Anti-CD37 CAR T cells CAR-37 T Cells In Hematologic Malignancies Completed USA 0
NCT04139304 Phase I Cyclophosphamide + Daratumumab + Doxorubicin + Etoposide + Prednisone + Vincristine Sulfate A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma Recruiting USA 0
NCT04160195 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Terminated USA 0
NCT04161118 Phase II huCART19 TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (TIGER-CTL019) Terminated DEU 0
NCT04161248 Phase I Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Venetoclax Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Recruiting CAN 0
NCT04182204 Phase III Gemcitabine + Oxaliplatin + Rituximab Gemcitabine + Oxaliplatin + Polatuzumab vedotin-piiq + Rituximab A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 9
NCT04205409 Phase II Nivolumab Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies Active, not recruiting USA 0
NCT04205838 Phase II Anakinra + axicabtagene ciloleucel + Cyclophosphamide + Fludarabine Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Recruiting USA 0
NCT04231747 Phase I CC-97540 A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting USA | CAN 0
NCT04231877 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma Suspended USA 0
NCT04243499 Phase I ICT01 First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) Recruiting USA | GBR | FRA | ESP | DEU | BEL 0
NCT04254107 Phase I SGN-TGT Pembrolizumab + SGN-TGT A Safety Study of SGN-TGT in Patients With Advanced Cancer Terminated USA | ITA | GBR | FRA | ESP | CAN 0
NCT04257578 Phase Ib/II Acalabrutinib + axicabtagene ciloleucel Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Recruiting USA 0
NCT04263584 Phase II Copanlisib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (COPA-R-CHOP) Active, not recruiting DEU 0
NCT04277637 Phase I BGB-11417 + Zanubrutinib BGB-11417 Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies Recruiting USA | NZL | ITA | GBR | ESP | DEU | AUS 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Recruiting AUS 1
NCT04283097 Phase I KPG-818 Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Recruiting USA 0
NCT04305444 Phase II DTRMWXHS-12 + Everolimus + Pomalidomide Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas Recruiting USA 0
NCT04314843 Phase Ib/II axicabtagene ciloleucel + Lenzilumab Cyclophosphamide + Fludarabine Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) Terminated USA 0
NCT04323956 Phase I Cyclophosphamide + Doxorubicin + Parsaclisib + Pegfilgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Parsaclisib + Pegfilgrastim + Prednisone + Rituximab + Vincristine Sulfate Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma Active, not recruiting USA 0
NCT04384484 Phase III Loncastuximab tesirine-lpyl + Rituximab Gemcitabine + Oxaliplatin + Rituximab Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5) Recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL 13
NCT04390737 Phase I HH2853 A Phase I Study to Evaluate the Safety and Clinical Activity of HH2853. Recruiting USA 1
NCT04401020 Phase I SAR442257 First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL Active, not recruiting USA | ESP 3
NCT04404283 Phase III Lenalidomide + Rituximab Brentuximab vedotin + Lenalidomide + Rituximab Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (ECHELON-3) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 6
NCT04408638 Phase III Obinutuzumab Gemcitabine + Oxaliplatin + Rituximab Gemcitabine + Glofitamab-gxbm + Oxaliplatin A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting USA | GBR | FRA | ESP | DEU | BEL | AUS 7
NCT04419909 Phase I huCART19 Retreatment With CTL019/CTL119 Not yet recruiting USA 0
NCT04433182 Phase II Bendamustine + Copanlisib + Rituximab Copanlisib Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma Active, not recruiting ITA 0
NCT04442022 Phase II Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Selinexor A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting USA | ITA | ESP | AUT 3
NCT04479267 Phase II Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisolone + Rituximab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Methylprednisolone + Polatuzumab vedotin-piiq + Rituximab Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma Recruiting USA 0
NCT04491370 Phase Ib/II Polatuzumab vedotin-piiq Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma Recruiting USA 0
NCT04500587 Phase I ZN-d5 Phase 1 First in Human Study of ZN-d5 as a Single Agent Recruiting ESP | AUS 5
NCT04502446 Phase I CTX130 A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies Active, not recruiting USA | CAN | AUS 0
NCT04502706 Phase I FSI-189 FSI-189 + Rituximab Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma Terminated USA 0
NCT04512716 Phase I Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells + Iomab-B Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT04517435 Phase Ib/II Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate + zandelisib ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma Active, not recruiting USA 0
NCT04529772 Phase III Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT04531046 Phase II axicabtagene ciloleucel Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation Active, not recruiting FRA | BEL 0
NCT04535102 Phase II Bendamustine + Polatuzumab vedotin-piiq + Rituximab POLA+BR for Relapsed or Refractory DLBCL Withdrawn 0
NCT04540796 Phase I JNJ-75348780 A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Active, not recruiting USA | GBR | FRA | ESP | AUS 3
NCT04545762 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT04546620 Phase II Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (REMoDL-A) Recruiting GBR 0
NCT04555811 Phase I FT596 + Rituximab FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL Active, not recruiting USA 0
NCT04572763 Phase Ib/II Copanlisib + Venetoclax Copanlisib Plus Venetoclax in R/R DLBCL Active, not recruiting USA 0
NCT04594642 Phase I TNB-486 A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Recruiting USA | AUS 3
NCT04594798 Phase II Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL Recruiting USA 0
NCT04604067 Phase II Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. Recruiting ITA 1
NCT04607772 Phase Ib/II Selinexor + Venetoclax Ibrutinib + Rituximab + Selinexor Lenalidomide + Rituximab + Selinexor Lenalidomide + Selinexor + Tafasitamab-cxix Bendamustine + Rituximab + Selinexor Polatuzumab vedotin-piiq + Rituximab + Selinexor Bendamustine + Polatuzumab vedotin-piiq + Rituximab + Selinexor Gemcitabine + Oxaliplatin + Rituximab + Selinexor Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Suspended USA 0
NCT04608487 Phase I Cyclophosphamide + Fludarabine axicabtagene ciloleucel Axi-cel in CNS Lymphoma Active, not recruiting USA 0
NCT04623541 Phase Ib/II Epcoritamab-bysp Epcoritamab-bysp + Venetoclax Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 3
NCT04628494 Phase III Gemcitabine + Oxaliplatin + Rituximab Epcoritamab-bysp Bendamustine + Rituximab A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT04630756 Phase Ib/II Acalabrutinib + AZD4573 AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer. Active, not recruiting USA | GBR | FRA | ESP | CAN | AUS 3
NCT04640779 Phase I Choline salicylate + Selinexor Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Residual, Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT04663347 Phase Ib/II Epcoritamab-bysp Cisplatin + Cytarabine + Dexamethasone + Epcoritamab-bysp + Rituximab Epcoritamab-bysp + Gemcitabine + Oxaliplatin Epcoritamab-bysp + Lenalidomide + Rituximab Bendamustine + Epcoritamab-bysp + Rituximab Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2) Recruiting USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS 5
NCT04665765 Phase II Polatuzumab vedotin-piiq Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting USA 0
NCT04676360 Phase II belantamab mafodotin-blmf Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma Recruiting USA 0
NCT04703686 Phase II Glofitamab-gxbm + Obinutuzumab Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy Active, not recruiting FRA 0
NCT04739813 Phase I Ibrutinib + Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq + Prednisone + Venetoclax Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma Recruiting USA 0
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04775745 Phase I LP-168 Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. Recruiting USA 0
NCT04790903 Phase I Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab + Venetoclax A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting USA | ITA | FRA | ESP 0
NCT04799275 Phase II Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Recruiting USA 0
NCT04809467 Phase Ib/II Parsaclisib + Tafasitamab-cxix A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 0
NCT04824092 Phase III Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 19
NCT04830137 Phase I NX-2127 A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Active, not recruiting USA 0
NCT04833114 Phase III Carboplatin + Etoposide + Ifosfamide + Rituximab Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE) Recruiting GBR | ESP | DEU | AUT 0
NCT04836195 Phase I PCLX-001 Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma Recruiting CAN 0
NCT04842877 Phase II DS-3201b Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma Active, not recruiting FRA | BEL 0
NCT04844866 Phase II Bendamustine + Polatuzumab vedotin-piiq + Rituximab Gemcitabine + Oxaliplatin + Rituximab Zamtocabtagene autoleucel Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU) Recruiting NLD | ITA | FRA | ESP | DEU | BEL | AUT 5
NCT04850495 Phase I Cyclophosphamide + Doxorubicin + Rituximab + Vincristine Sulfate + Zanubrutinib Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT04853329 Phase Ib/II CPO107 Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma Suspended USA 0
NCT04855253 Phase Ib/II E7777 Study of E7777 Prior to Kymriah for R/R DLBCL Recruiting USA 0
NCT04882163 Phase Ib/II Cisplatin + Dexamethasone + Gemcitabine + Iberdomide + Rituximab Lenalidomide + Tafasitamab-cxix Iberdomide + Polatuzumab vedotin-piiq + Rituximab Iberdomide + Tafasitamab-cxix Bendamustine + Polatuzumab vedotin-piiq + Rituximab Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma Withdrawn USA | GBR | FRA | ESP | BEL | AUT 2
NCT04889716 Phase II Glofitamab-gxbm + Obinutuzumab Mosunetuzumab-axgb CAR-T Followed by Bispecific Antibodies Recruiting USA 0
NCT04890236 Phase I Tisagenlecleucel Duvelisib Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study Recruiting USA 0
NCT04903197 Phase I Lenalidomide + VAY736 VAY736 Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma Recruiting USA | ITA | ESP | DEU | AUS 4
NCT04906902 Phase Ib/II Acalabrutinib Acalabrutinib in CNSL Recruiting USA 0
NCT04914741 Phase Ib/II Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisolone + Rituximab A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (COALITION) Active, not recruiting AUS 0
NCT04920617 Phase II Maveropepimut-S Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab DPX-Survivac, Alone or in Combination With Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting USA | NZL | FRA | ESP | CAN | AUS 4
NCT04933617 Phase I Copanlisib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Completed USA 0
NCT04974216 Phase II Lenalidomide + Rituximab + Tafasitamab-cxix Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older Recruiting FRA | BEL 0
NCT04975555 Phase II Siltuximab Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Recruiting USA 0
NCT04978584 Phase II Acalabrutinib + Cyclophosphamide + Doxorubicin + Lenalidomide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Acalabrutinib + Lenalidomide + Rituximab + Tafasitamab-cxix Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study Recruiting USA 0
NCT04980222 Phase II Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisone + Rituximab + Vincristine Sulfate A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma Recruiting USA | NLD | FRA | ESP 2
NCT05005442 Phase II MK-7684A A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 10
NCT05011058 Phase II CHR-3996 CHR-3996 + Valganciclovir An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 7
NCT05020015 Phase II iC9-CAR.19-IL15-Transduced CB-NK Cyclophosphamide + Fludarabine A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Active, not recruiting USA 0
NCT05020678 Phase I Cyclophosphamide + Fludarabine NKX019 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Recruiting USA | AUS 0
NCT05052528 Phase I Anti-CD19 CAR-T cells + Cyclophosphamide + Fludarabine Anti-CD19 CAR-T cells + Cyclophosphamide + Fludarabine + Rituximab Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT05065866 Phase I Azacitidine + Duvelisib Duvelisib in Combination With CC-486 in Lymphoid Malignancy Active, not recruiting USA 0
NCT05075603 Phase I Tisagenlecleucel A Study to Evaluate the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) Post-Tisagenlecleucel (Kymriah) in Relapsed/Refractory Large B-cell Lymphoma Subjects Recruiting USA 0
NCT05098613 Phase I CD19/CD22 CAR T cells Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients Recruiting USA 0
NCT05107674 Phase I NX-1607 A Study of NX-1607 in Adults With Advanced Malignancies Recruiting USA | GBR 0
NCT05121103 Phase I EZM0414 A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT05131022 Phase I NX-5948 Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting USA | NLD | GBR 0
NCT05139017 Phase II Bendamustine + Rituximab + VLS-101 Gemcitabine + Oxaliplatin + Rituximab + VLS-101 Bendamustine + Rituximab Gemcitabine + Oxaliplatin + Rituximab A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) Recruiting USA | ITA | GBR | FRA | CAN 6
NCT05144009 Phase II Loncastuximab tesirine-lpyl + Rituximab A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) Completed USA | ITA | ESP 1
NCT05144841 Phase II VLS-101 A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) Active, not recruiting USA | ITA | FRA | ESP | CAN 12
NCT05153330 Phase I BMF-219 Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL With KMT2A/ MLL1r, NPM1 and Other Mutations Recruiting USA | NLD | ITA | ESP 1
NCT05169515 Phase I Glofitamab-gxbm + Iberdomide CC-99282 + Glofitamab-gxbm CC-99282 + Mosunetuzumab-axgb Iberdomide + Mosunetuzumab-axgb A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma Recruiting USA | ITA | GBR | ESP 1
NCT05171647 Phase III Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Tocilizumab Gemcitabine + Oxaliplatin + Rituximab A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO) Recruiting USA | NZL | CAN 11
NCT05179603 Phase II THOR-707 Pembrolizumab + THOR-707 A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) Active, not recruiting ESP 2
NCT05202782 Phase II Zanubrutinib Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma Recruiting USA 0
NCT05205161 Phase Ib/II AZD0466 A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma Terminated USA | ITA | FRA | ESP | AUS 2
NCT05205252 Phase Ib/II Lenalidomide + Tafasitamab-cxix + Tazemetostat Daratumumab + Dexamethasone + Pomalidomide + Tazemetostat Daratumumab and hyaluronidase-fihj + Dexamethasone + Pomalidomide + Tazemetostat Mosunetuzumab-axgb + Tazemetostat Lenalidomide + Tazemetostat Acalabrutinib + Tazemetostat A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. (ARIA) Withdrawn USA 0
NCT05206357 Phase I Epcoritamab-bysp Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 6
NCT05207670 Phase II Mosunetuzumab-axgb + Tocilizumab A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) Recruiting USA 1
NCT05211336 Phase I Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System Active, not recruiting USA 0
NCT05221645 Phase II Carboplatin + Etoposide + Ifosfamide + Rituximab Carboplatin + Etoposide + Ifosfamide + Pembrolizumab + Rituximab Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (P+R-ICE) Recruiting GBR 0
NCT05222555 Phase Ib/II Lenalidomide + Tafasitamab-cxix Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (MINDway) Active, not recruiting USA | ITA | FRA | ESP | AUT 4
NCT05233033 Phase I KT-413 Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL Suspended USA | GBR 0
NCT05253495 Phase II Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Vincristine Sulfate Cytarabine + Etoposide + Polatuzumab vedotin-piiq + Rituximab Cytarabine + Etoposide + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Cytarabine + Methotrexate + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Rituximab + Vinblastine Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL) Recruiting USA 0
NCT05255601 Phase Ib/II Nivolumab + Relatlimab A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS 0
NCT05260957 Phase II Mosunetuzumab-axgb + Polatuzumab vedotin-piiq CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Recruiting USA 0
NCT05270057 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (LONCA) Recruiting USA 0
NCT05272384 Phase I Decitabine and Cedazuridine + Nivolumab Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Recruiting USA 0
NCT05275504 Phase I TT-01488 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Recruiting USA 0
NCT05279300 Phase I CS5001 A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas Recruiting USA | AUS 1
NCT05283720 Phase II Epcoritamab-bysp + Lenalidomide Epcoritamab-bysp + Ibrutinib + Lenalidomide Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Polatuzumab vedotin-piiq + Prednisone + Rituximab A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma Recruiting USA | NLD | FRA | ESP | DEU 7
NCT05296525 Phase Ib/II GDA-201 Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL Terminated USA 0
NCT05315713 Phase Ib/II Mosunetuzumab-axgb + Tiragolumab + Tocilizumab Atezolizumab + Mosunetuzumab-axgb + Tiragolumab + Tocilizumab An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma Completed USA | GBR | DEU | CAN | BEL | AUS 0
NCT05319028 Phase II Mivavotinib Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated USA 0
NCT05328102 Phase II Lenalidomide + Tafasitamab-cxix Lenalidomide + Tafasitamab-cxix + XmAb13676 Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in R/R DLBCL Terminated USA | FRA | ESP 0
NCT05338346 Phase I ATG-018 A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM) Recruiting AUS 0
NCT05346809 Phase II Isatuximab Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma Recruiting USA 0
NCT05348889 Phase Ib/II 1A46 First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies Recruiting USA 0
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT05359211 Phase I NKTR-255 Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Recruiting USA 0
NCT05360238 Phase Ib/II MB-106 Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL Recruiting USA 0
NCT05365659 Phase I IKS03 IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Recruiting USA | CAN | AUS 0
NCT05371054 Phase Ib/II Prednisone + Venetoclax + VIP152 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Recruiting USA 0
NCT05406401 Phase II Prednisolone Prednisone Cyclophosphamide + Doxorubicin + Rituximab + VLS-101 A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) Recruiting ITA | ESP | CAN 4
NCT05412290 Phase I Mosunetuzumab-axgb Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma Recruiting USA 0
NCT05424822 Phase I JNJ-80948543 A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA | FRA | AUS 4
NCT05429268 Phase III Lenalidomide + Tafasitamab-cxix Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) Recruiting GBR 13
NCT05442515 Phase Ib/II CD19/CD22 CAR T cells Cyclophosphamide + Fludarabine CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Recruiting USA 0
NCT05451810 Phase II Epcoritamab-bysp A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma Recruiting USA 1
NCT05453396 Phase II Loncastuximab tesirine-lpyl Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Recruiting USA 0
NCT05455697 Phase Ib/II Cyclophosphamide + Doxorubicin + Prednisone + Retifanlimab + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT05459571 Phase II axicabtagene ciloleucel + Cyclophosphamide + Dexamethasone + Fludarabine Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (ZUMA-24) Active, not recruiting USA 0
NCT05464329 Phase I Mosunetuzumab-axgb Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma Recruiting USA 0
NCT05464719 Phase II Loncastuximab tesirine-lpyl A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy Recruiting USA 0
NCT05498220 Phase II Cisplatin + Dexamethasone + Gemcitabine + Hyaluronidase + Polatuzumab vedotin-piiq + Rituximab + Sargramostim Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT05507541 Phase II Pembrolizumab + TTI-622 Pembrolizumab + TTI-621 TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT05512390 Phase I ABBV-319 A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) Recruiting USA | CAN | AUS 1
NCT05533775 Phase Ib/II Glofitamab-gxbm Carboplatin + Etoposide + Glofitamab-gxbm + Ifosfamide + Rituximab Tocilizumab Obinutuzumab A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO) Recruiting USA | ITA | FRA | ESP | DEU | AUS 2
NCT05537766 Phase II Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25) Recruiting USA | NLD | ITA | FRA | ESP | DEU | AUT 1
NCT05546268 Phase Ib/II MRT-2359 Study of Oral MRT-2359 in Selected Cancer Patients Recruiting USA | CAN 0
NCT05565417 Phase Ib/II IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05578976 Phase III Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2) Recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 20
NCT05583149 Phase II Acalabrutinib + Lisocabtagene maraleucel Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas Recruiting USA 0
NCT05588440 Phase Ib/II Cyclophosphamide + Fludarabine ONCT-808 A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies Recruiting USA 0
NCT05600686 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT05605899 Phase III Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate axicabtagene ciloleucel + Cyclophosphamide + Fludarabine A Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 1
NCT05607420 Phase Ib/II Alemtuzumab UCART20X22 Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) Recruiting USA | FRA | ESP 0
NCT05615636 Phase II Lenalidomide + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Tafasitamab-cxix A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL Recruiting USA 0
NCT05618028 Phase I ABBV-525 Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets Recruiting USA | GBR | FRA | ESP | BEL | AUS 1
NCT05618366 Phase I Tazemetostat + Venetoclax Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT05626322 Phase II Lenalidomide + Tafasitamab-cxix + TTI-622 Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Recruiting USA 3
NCT05633615 Phase II Cyclophosphamide + Fludarabine axicabtagene ciloleucel + Lisocabtagene maraleucel + Tisagenlecleucel Polatuzumab vedotin-piiq Mosunetuzumab-axgb Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT05641428 Phase II axicabtagene ciloleucel ARI-0001 Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161) Recruiting NLD 0
NCT05660395 Phase I Loncastuximab tesirine-lpyl A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) Recruiting USA 3
NCT05660967 Phase II Epcoritamab-bysp Epcoritamab-bysp + Lenalidomide Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3) Recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT 4
NCT05664217 Phase II NKTR-255 NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma Recruiting USA 0
NCT05672251 Phase II Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT05702853 Phase Ib/II CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL Recruiting USA 0
NCT05714345 Phase II Cyclophosphamide + Fludarabine ALLO-647 + Cyclophosphamide + Fludarabine ALLO-501A Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPAND) Recruiting USA | BEL | AUT 0
NCT05737628 Phase I BYON4228 + Rituximab First-in-human Dose Escalation and Expansion Study With the SIRPalpha-directed Monoclonal Antibody BYON4228 Recruiting NLD | ITA | GBR | ESP 0
NCT05753501 Phase I ABBV-101 Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies Recruiting USA 2
NCT05755087 Phase I BC2059 Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma Recruiting USA 0
NCT05757219 Phase II axicabtagene ciloleucel + Itacitinib Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy Recruiting USA 0
NCT05757700 Phase I 19(T2)28z1xx TRAC CAR-T cells Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma Recruiting USA 0
NCT05773040 Phase I JV-213 A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas Active, not recruiting USA 0
NCT05780034 Phase I AC0676 A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies Recruiting USA 0
NCT05794958 Phase I axicabtagene ciloleucel Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel Recruiting USA 0
NCT05797233 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies Recruiting USA 0
NCT05798897 Phase I MT-601 Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO) Recruiting USA 0
NCT05800366 Phase II Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisone + Rituximab A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT05801913 Phase I CMV-CD19 CAR T-cells + Multi-antigen CMV-modified vaccinia Ankara vaccine Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT05820841 Phase III Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (ARCHED) Recruiting DEU 0
NCT05821088 Phase II Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Tafasitamab-cxix Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Recruiting USA 0
NCT05826535 Phase Ib/II IMPT-314 Study of IMPT-314 in R/R Aggressive B-cell Recruiting USA 0
NCT05828589 Phase I BGB-21447 A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies Recruiting AUS 1
NCT05873712 Phase II Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel + Zanubrutinib Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome Recruiting USA 0
NCT05878184 Phase I Cyclophosphamide + Fludarabine SC291 Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) Recruiting USA | AUS 0
NCT05879744 Phase I CLN-978 A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) Active, not recruiting USA 0
NCT05890352 Phase II Lenalidomide + Tafasitamab-cxix Lenalidomide + Tafasitamab-cxix + Tazemetostat Lenalidomide + Tafasitamab-cxix + Zanubrutinib Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Recruiting USA 0
NCT05896163 Phase Ib/II Glofitamab-gxbm + Obinutuzumab + TTI-622 A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. Recruiting USA 2
NCT05908409 Phase Ib/II IDP-121 A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies Recruiting ESP 0
NCT05929716 Phase II Hu5F9-G4 + Rituximab An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Withdrawn 0
NCT05934448 Phase II Pembrolizumab Pembro Plus CAR T-cell Therapy in R/R in PMBCL Recruiting USA 0
NCT05934838 Phase I Tazemetostat A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas Recruiting USA 0
NCT05950165 Phase Ib/II CHO-H01 A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma Recruiting USA 1
NCT05950334 Phase I Bendamustine + FT522 + Rituximab Cyclophosphamide + Fludarabine + FT522 + Rituximab FT522 + Rituximab FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) Recruiting USA 0
NCT05967416 Phase I SIRPant-M Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Recruiting USA 0
NCT05972720 Phase II Cyclophosphamide + Fludarabine CRG-022 A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma Recruiting USA 0
NCT05989204 Phase I HuCART19-IL18 TmCD19-IL18 in CD19+ Cancers Recruiting USA 0
NCT06014762 Phase I P-CD19CD20-ALLO1 P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies Recruiting USA 0
NCT06015880 Phase I Lenalidomide + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT06026319 Phase I CD79b-19 CAR T cells Cyclophosphamide + Fludarabine CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Recruiting USA 0
NCT06045247 Phase II Cyclophosphamide + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT06079164 Phase I KITE-197 Cyclophosphamide + Fludarabine Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma Recruiting USA | CAN | AUS 0
NCT06088654 Phase Ib/II IPH6501 Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma Recruiting USA | AUS 0
NCT06090539 Phase I BMS-986458 + Rituximab BMS-986458 A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas Recruiting USA | NLD | FRA | ESP 1
NCT06091865 Phase III Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Odronextamab + Prednisone + Vincristine Sulfate A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3) Recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 7
NCT06132503 Phase I LP-284 A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors Recruiting USA 0
NCT06173518 Phase I Obecabtagene autoleucel A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) Recruiting GBR 0
NCT06208735 Phase I CLIC-2201 CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies Not yet recruiting CAN 0
NCT06238648 Phase II Epcoritamab-bysp Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy Not yet recruiting USA 0
NCT06242834 Phase II Pembrolizumab + Tazemetostat Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Not yet recruiting USA 0
NCT06249191 Phase Ib/II Cyclophosphamide + Doxorubicin + Etoposide + Mosunetuzumab-axgb + Prednisone + Vincristine Sulfate Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma Not yet recruiting USA 0
NCT06254495 Phase I SGN-35C A Safety Study of SGN-35C in Adults With Advanced Cancers Recruiting USA 0
NCT06271057 Phase II CC-99282 Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse Not yet recruiting FRA 0
NCT06285422 Phase I Cyclophosphamide + Fludarabine SC262 Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) Recruiting USA 0
NCT06290622 Phase I INCAGN02385 + INCAGN02390 + Retifanlimab PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Not yet recruiting USA 0
NCT06343376 Phase I EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Not yet recruiting USA 0
NCT06356129 Phase III CC-99282 + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) Not yet recruiting USA | NZL | FRA | ESP | DEU | CAN | AUT | AUS 29
NCT06392477 Phase I DR-0201 A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Recruiting AUS 4